Compare JPMorgan Chase & Co (JPM) vs McKesson Corporation (MCK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
JPMorgan Chase & Co vs McKesson Corporation — how do they compare? JPMorgan Chase & Co trades at $365.09 (market cap $962.37B), while McKesson Corporation trades at $891.17 (market cap $105.14B). The key difference: JPMorgan Chase & Co is far larger — about 9.2× McKesson Corporation's market cap, and JPMorgan Chase & Co pays the higher dividend (1.66%). Which is the better fit depends on your goals.
| JPM | MCK | |
|---|---|---|
Market Cap | $962.37B | $105.14B |
Volume | 10,479,943 | — |
Sector | Financials | Health |
52-Week High | $362.04 | $995.69 |
52-Week Low | $282.84 | $659.01 |
Dividend Yield | 1.66% | 0.42% |
Enterprise Value | — | $111.67B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JPMorgan Chase (JPM) trades at $359.79, up 0.63% today, with a bullish technical signal from moving averages and a consensus analyst price target of $374.18. Recent earnings have shown strength with beats in Q1 and Q2 2026, though Q4 2025 missed expectations. Revenue and net income have grown steadily, with 2025 revenue at $181.85B and net income at $57.05B, though cash flow from operations remains negative. The stock exhibits strong institutional interest and a moderate buy rating from analysts.
The outlook for JPM is positive, supported by robust profitability metrics like an 18.43% ROE and a net income margin of 33.38%. Key risks include geopolitical tensions impacting banking sectors and persistent negative operating cash flows. Upside potential exists if the company meets or exceeds future earnings expectations, with the next catalyst being Q3 2026 results.
McKesson (MCK) trades at $879.87, up 1.18% today, with strong momentum from recent earnings beats and raised guidance. The stock shows bullish technical signals, supported by robust revenue growth and solid cash flow generation. Recent news highlights strength in specialty drugs and oncology, driving positive sentiment.
Outlook remains favorable with a consensus price target of $990.67, though thin profit margins and high liabilities pose risks. Continued execution on growth initiatives and cost discipline are key for sustained upside, while macroeconomic pressures and competitive dynamics require monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About JPMorgan Chase & Co
JPMorgan Chase & Co. provides global financial services and retail banking. The Company provides services such as investment banking, treasury and securities services, asset management, private banking, card member services, commercial banking, and home finance. JP Morgan Chase serves business enterprises, institutions, and individuals.
Read more on JPM →About McKesson Corporation
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →
